New hope for lymphoma patients who failed CAR T-Cell treatment
NCT ID NCT07003295
Summary
This study tests whether a two-drug combination can help patients with mantle cell lymphoma whose cancer has returned or stopped responding after they received CAR T-cell therapy. The treatment uses glofitamab, which helps the immune system target cancer cells, along with obinutuzumab. Researchers want to see if this approach is safe and effective for this specific group of patients who have limited treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
JHU Sidney Kimmel Comprehensive Cancer Center LAO
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.